AI-enhanced ECGs may soon assess overall health

By

Scientists have trained an artificial intelligence tool to predict sex and estimate age from electrocardiogram readouts. They suggest that, with further development, the tool could soon be helping doctors to assess the overall health of their patients.

An electrocardiogram, also known as an ECG or EKG, is a painless, simple test that records the electrical activity of a person’s heart.

A recent paper in the journal Circulation: Arrhythmia and Electrophysiology, describes how the team developed an artificial intelligence (AI) tool to predict sex and estimate age from ECG data. If you want to know more about this news, click here.

Posted in News, Science, Technology.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    18 junio, 2019

    5 Pediatric Orthopedic Devices you need to know

    The National Capital Consortium for Pediatric Device Innovation recently recognized five pediatric orthopedic devices that could improve scoliosis treatment, clubfoot assessment, and surgical imaging. If you want to read more about this news click here.

  •
    10 octubre, 2019

    Human trials could start soon on Adam’s 3D printed bone grafts

    Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year. Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology …

  •
    10 octubre, 2019

    ‘Electronic tongues’ may help diagnose early stage bladder cancer

    New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe …

  •
    10 octubre, 2019

    Medtronic announces Infuse spine trial

    Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures. The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, …